We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+9.98%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$142M
AUM Growth
-$2.52M
Cap. Flow
-$171K
Cap. Flow %
-0.12%
Top 10 Hldgs %
63.22%
Holding
44
New
12
Increased
5
Reduced
7
Closed
16

Top Buys

Rank Stock Value
1
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$6.37M
2
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$6.01M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$5.16M
4
OCRX
Ocera Therapeutics, Inc.
OCRX
+$4.93M
5
VCYT icon
Veracyte
VCYT
+$4.61M

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$8.31M
2
GENT
GENTIUM SPA ADS
GENT
+$6.1M
3
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$4.6M
4
ALBO
Albireo Pharma Inc
ALBO
+$4.2M
5
TRIB
Trinity Biotech
TRIB
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 44.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRM
26
DELISTED
Streamline Health Solutions
STRM
$586K 0.41%
5,598
-26,127
-82% -$2.87M
RMTI icon
27
Rockwell Medical
RMTI
$28.4M
$418K 0.3%
+364
New +$502K
ACHV icon
28
Achieve Life Sciences
ACHV
$659M
– –
-120
Closed -$2.45M
AMRN
29
CALL
Amarin Corp
AMRN
$298M
– –
-25,000
Closed -$3.16M
GERN icon
30
Geron
GERN
$828M
– –
-2,626,152
Closed -$8.31M
PTN
31
Palatin Technologies
PTN
$13.7M
– –
-154
Closed -$133K
TRIB
32
Trinity Biotech
TRIB
$7.83M
– –
-1,260
Closed -$4.11M
TXMD icon
33
TherapeuticsMD
TXMD
$23.5M
– –
-8,333
Closed -$1.22M
ALIM
34
CALL
DELISTED
Alimera Sciences
ALIM
– –
-4,953
Closed -$279K
ONCT
35
PUT
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-41
Closed -$117K
ALBO
36
DELISTED
Albireo Pharma Inc
ALBO
– –
-44,483
Closed -$4.2M
SRGA
37
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
– –
-20,201
Closed -$2.27M
ARQL
38
DELISTED
Arqule Inc
ARQL
– –
-373,926
Closed -$871K
PTX
39
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-29,681
Closed -$807K
DRTX
40
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
– –
-508,472
Closed -$4.6M
NDZ
41
DELISTED
NORDION INC COM STK (CDA)
NDZ
– –
-299,902
Closed -$2.59M
GENT
42
DELISTED
GENTIUM SPA ADS
GENT
– –
-224,767
Closed -$6.1M
GIVN
43
DELISTED
GIVEN IMAGING LTD
GIVN
– –
-118,000
Closed -$2.27M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2013 Portfolio in Review

As of Q4 2013, Great Point Partners held 44 positions worth $142M, down 1.7% from $144M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Great Point Partners's Q4 2013 filing shows 12 new, 5 increased, 7 reduced and 16 closed positions. Its largest new stake was Infinity Pharmaceuticals, Inc.: 451,100 shares worth $6.23M. The largest sale was Geron, an estimated $8.31M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 42% a quarter earlier.

  • Great Point Partners's largest Q4 2013 buy was Infinity Pharmaceuticals, Inc.: 451,100 shares worth $6.23M.
  • Great Point Partners added most to Protalix BioTherapeutics in Q4 2013, an estimated $2.53M increase.
  • Great Point Partners's biggest Q4 2013 reduction was Streamline Health Solutions, cutting an estimated $2.87M.
  • Great Point Partners fully exited Geron in Q4 2013, selling an estimated $8.31M.
  • Great Point Partners's ten largest holdings make up 63% of its $142M portfolio in Q4 2013.
  • Great Point Partners opened 12 new positions and closed 16 in Q4 2013.
  • Great Point Partners's portfolio value fell 1.7% quarter-over-quarter to $142M.

Based on Great Point Partners's 13F filing for Q4 2013, filed 14 Feb 2014.